Investments & digital assets › F8949.D.X50
F8949.D.X50 · federal · F8949 line D.X50
Delmar Pharma (acquired 2024-03-19, sold 2025-11-17; proceeds 132.37, basis 155.75)
-23.38
engine v3
not yet verified
How this number was built
R-8949-LOT One line per sale: proceeds minus basis plus adjustment. Broker basis is used as reported unless a supplemental statement for the same lot is matched.
Sources (6) — where the inputs came from
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 24 · field X50_desc · “Lot X50 description”
read as “Delmar Pharma” → Delmar Pharma
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 24 · field X50_acq · “Lot X50 date acquired”
read as “03/19/2024” → 2024-03-19
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 24 · field X50_sold · “Lot X50 date sold”
read as “11/17/2025” → 2025-11-17
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 24 · field X50_proceeds · “Lot X50 proceeds”
read as “132.37” → 132.37
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 24 · field X50_basis · “Lot X50 cost basis”
read as “155.75” → 155.75
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 24 · field X50_wash · “Lot X50 wash sale loss disallowed”
read as “0.00” → 0
99%
Flows into
History — nothing is overwritten
v1 · 2026-03-04: -23.38v2 · 2026-03-19: -23.38v3 · 2026-06-23: -23.38
Adjust this number
Evidence & discussion
Record how you verified it